Qualification and Validation of Single-Use Shipping Systems

Author(s)BP Nicolas Voute, Elisabeth Vachette, Delphine Audubey

In this article, the authors look at the limitations of the validation for a single-use shipping system and provide a perspective on what shipping validation means.

As the biotech industry evolves, there are mounting concerns about the transportation, security, and robustness of cell-culture media, intermediate, or bulk drug substance (BDS). Safe, stable, and closed systems are needed when sterile products are shipped in single-use bags. In this article, the authors look at the limitations of the validation for a single-use shipping system and provide a perspective on what shipping validation means.

Download

Pharmaceutical Technology’s 2016 Bioprocessing and Sterile Manufacturing eBook

Articles in this issue

over 10 years ago

Article

Measuring and Removing Genotoxic Impurities

over 10 years ago

Article

The Evolution of Planning, Design, and Engineering—Flexibility Takes Center Stage

over 10 years ago

Article

Revised ISO Cleanroom Standards Improve Air Cleanliness Classification

over 10 years ago

Article

Lessons Learned Accelerate Vaccine Development

over 10 years ago

Article

Protecting the Product and the Patient

over 10 years ago

Article

Deconstructing the Regulatory Spiral

over 10 years ago

Article

Non-Sterile is Non-Sterile: A Reality Check on Microbial Control Expectations

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

October 30th, 2026

PharmTech Weekly Roundup—October 30, 2026: Formulation, AI, and NAMs at AAPS PharmSci 360

The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.

female worker wearing uniform inside factory clean room conducting inspection on manufacturing machine holding digital tablet monitor process carefully | Image Credit: ©eakgrungenerd -stock.adobe.com

October 30th, 2026

FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations

The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.

October 26th, 2026

PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization

This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.

Interface acceptance testing ties each pen injector assembly to its result, reject action, and data.

October 26th, 2026

From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly

How to test pen injector assembly interfaces from URS to FAT and SAT: verify part tracking, reject confirmation, restarts, and data transfer evidence.

October 23rd, 2026

Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight

Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.

AI results in pharma manufacturing nearly doubled to 53%—but GMP decisions still need human sign-off

October 23rd, 2026

Pharma Leaders Weigh in On AI's Measurable Results In 2026

Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.